Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Imada EL, Wilks C, Langmead B, Marchionni L. REPAC: analysis of alternative polyadenylation from RNA-sequencing data. Genome Biol. 2023;24(1):22.

Suben J, Goyal A, Rao R, Sung S. Diagnostic implication of extracellular mucin in pancreatic/biliary brushing and stent cytology. Cancer Cytopathol. 2023;131(6):360-364.

Shen B, Saito A, Ueda A, Fujita K, Nagamatsu Y, Hashimoto M, et al. Development of multiple AI pipelines that predict neoadjuvant chemotherapy response of breast cancer using H&E-stained tissues. J Pathol Clin Res. 2023;9(3):182-194.

Van Emmenis L, Ku S-, Gayvert K, Branch JR, Brady NJ, Basu S, et al. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer Res Commun. 2023;3(8):1447-1459.

Osman AE, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, et al. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv. 2023;7(9):1910-1914.

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, et al. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. Mol Cancer Res. 2023;21(3):253-260.

Zhao Z, Kumanovics A, Love T, Melanson SE, Meng QH, Wu AH, et al. T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection. Viruses. 2023;15(3).

Fischer GM, Lindeman NI, Ligon AH, Russell-Goldman E. Proliferating Pilar Tumors Are Characterized by Recurrent 15q, 6q, and 6p22.2 Alterations. Am J Dermatopathol. 2023;45(4):217-226.

Folarin OS, Siddiqui MT. Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria. Cancer Cytopathol. 2023;131(11):708-715.